Table 2.
Markers | Authors | Cut-off | Other content |
Survival (5-yr) |
|
OS | RFS | ||||
AFP | Zheng et al[12] | AFP ≤ 400 | Hangzhou criteria | 78.3% | 62.4% |
Toso et al[27] | AFP ≤ 400 | Total tumor volume ≤ 115 cm3 | None | None | |
Wan et al[20] | AFP ≤ 400 | Tumor ≤ 10 cm, no vascular and extrahepatic invasions | 73.7% | 74.4% | |
DCP | Ito et al[6] | DCP ≤ 400 | Tumor size ≤ 10 cm | 86.7% | None |
Soejima et al[13] | DCP ≤ 300 | Tumor size ≤ 5 cm | None | 93.8% (3-yr) | |
NLR | Xiao et al[43] | NLR < 4 | None | 61.5% | 60.7% |
AFP/CA199 | Wan et al[30] | AFP ≤ 400, CA199 ≤ 400 | None | 74.6% | 78.5% |
NLR/CRP | Na et al[47] | NLR < 6.0 or CRP < 1.0 | None | None | None |
DCP/AFP | Todo et al[35] | DCP ≤ 100, AFP ≤ 200 | Milan criteria | None | 96.4% |
Shindoh et al[36] | AFP ≤ 250, DCP ≤ 450 | Tokyo criteria | 84.0% | 96.8% |
AFP: Alpha fetoprotein; DCP: Des-Gamma-carboxy prothrombin; NLR: Neutrophil-to-lymphocyte ratio; OS: Overall survival; RFS: Relapse free survival.